Draft for Consultation
نویسندگان
چکیده
level: aDvanceD F or most biopharmaceuticals, potency is assessed in a bioassay by comparing dose–response curves of the test material and a reference standard. As with all analytical techniques, such assays require criteria by which their execution can be judged objectively to be valid, regardless of whether the desired or expected result is obtained for the test sample. The purpose of this paper is to provide guidance on setting assay acceptance criteria (AAC) for potency assays based on multiwell plates. Multiple components of the overall assay system — from instruments to incubation media — need to be within defined limits to permit execution of a valid assay, so they are tested for suitability either before or during the assay. Because of the complexity of bioassay systems, not every relevant factor can be controlled. Thus, it is necessary to rely strongly on analysis of data produced by each individual assay to determine whether that assay was executed correctly. This paper discusses criteria that can be applied to the assay results and the importance of assay design in selecting useful acceptance criteria.
منابع مشابه
Guideline on pharmaceutical development of medicines for paediatric use
Draft agreed by QWP February 2011 Draft agreed by SWP March 2011 Draft agreed by PDCO April 2011 Adoption by CHMP for release for consultation May 2011 End of consultation (deadline for comments) 31 December 2011 Revised version agreed by QWP for release for second consultation September 2012 Revised version agreed by PDCO for release for second consultation November 2012 Revised version adopte...
متن کاملGuideline on pharmaceutical development of medicines for paediatric use
Draft Agreed by QWP February 2011 Draft agreed by SWP March 2011 Draft agreed by PDCO April 2011 Adoption by CHMP for release for consultation May 2011 End of consultation (deadline for comments) 31 December 2011 Revised version agreed by QWP for release for second consultation September 2012 Revised version agreed by PDCO for release for second consultation November 2012 Revised version adopte...
متن کاملReflection paper on anthelmintic resistance
Draft agreed by CVMP Efficacy Working Party (EWP-V) February 2014 Adopted by CVMP for release for consultation 10 April 2014 Start of public consultation 23 April 2014 End of consultation (deadline for comments) 31 July 2014 Revised draft adopted by CVMP for release for second consultation 21 April 2016 Start of public consultation 29 April 2016 End of consultation (deadline for comments) 31 Ju...
متن کاملPublic consultation changes guidance on the use of health‐care interventions. An observational study
OBJECTIVES To investigate the responses to public consultation on draft guidance on interventional procedures (IP) for the UK National Health Services, and the changes made as a result of consultation. DESIGN Retrospective review of responses received during public consultation for 183 pieces of draft guidance, and subsequent changes made. SETTING The National Institute for Health and Care ...
متن کاملGuideline on non-clinical and clinical development of similar biological medicinal products containing recombinant human insulin and insulin analogues
Draft revision agreed by BMWP November 2012 Adopted by CHMP for release for consultation 13 December 2012 Start of public consultation 14 December 2012 End of consultation (deadline for comments) 30 June 2013 Draft revision agreed by BMWP April 2014 Adopted by CHMP for release for consultation 25 April 2014 Start of public consultation 30 April 2014 End of consultation (deadline for comments) 3...
متن کاملGuideline on clinical investigation of medicinal products in the treatment of Parkinson’s disease
Draft agreed by Efficacy Working Party June 2007 Adopted by CHMP for release for consultation 19 July 2007 End of consultation (deadline for comments) 31 January 2008 Agreed by Efficacy Working Party July 2008 Adopted by CHMP 24 July 2008 Date for coming into effect 1 February 2009 Updated draft agreed by CNS Working Party June 2012 Adopted by CHMP 21 June 2012 Start of public consultation n/a ...
متن کامل